Pregabalin Capsule
Product Images NDC 72162-1541

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72162-1541). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621541)

Label for Pregabalin Capsules 25 mg by Bryant Ranch Prepack. The label shows the NDC number 72162-1541, with 90 capsules per container. The label advises to keep drugs out of reach of children and store at room temperature 20-25°C (68-77°F). Manufactured by ScieGen Pharmaceuticals Inc. and repackaged by Bryant Ranch Prepack, Inc.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting the percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and a placebo group.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph showing the percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. Two lines represent treatment with Pregabalin 100 mg three times a day and placebo, illustrating comparative pain improvement outcomes.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and placebo, illustrating the differences in patient improvement across varying pain improvement thresholds.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph displays diminishing percentages of patients improved as percent pain improvement thresholds increase from 0 to 100.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. The graph compares three groups: Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line). The lines show a higher percentage of patients improved with both Pregabalin doses compared to placebo across the range of pain improvement percentages.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph showing responder rates (%) for Pregabalin doses compared to placebo in two studies, E1 and E3. The x-axis depicts treatment groups with doses ranging from placebo to 600 mg/day, while the y-axis shows responder rates from 0% to 60%. Statistically significant increases versus placebo are indicated by asterisks.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph showing seizure reduction measured as median percent change from baseline on the y-axis versus dose in mg/day on the x-axis. The graph includes data points from four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID, with significant p-values indicated. Dose levels range from 0 to 600 mg/day and seizure reduction from 0 to 60 percent.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. The graph includes four lines representing Pregabalin daily doses of 800 mg, 450 mg, 300 mg, and a placebo, illustrating pain improvement trends across these groups.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve graph comparing Pregabalin and placebo. The y-axis shows the estimated percentage of subjects without LTR (lack of treatment response), ranging from 0% to 100%, while the x-axis represents days from 0 to 180. The solid line represents Pregabalin, and the dashed line represents placebo, showing higher survival rates without LTR for Pregabalin over time.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over time from baseline to week 12, with Pregabalin and Placebo groups. The x-axis represents percent improvement, ranging from 0 to 100, and the y-axis shows the percent of subjects improved, also from 0 to 100. The solid line indicates Pregabalin, and the dashed line indicates Placebo, with Pregabalin showing higher percent improvement across the timeline.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved from baseline to week 16 between Pregabalin and Placebo. The x-axis represents the percent improvement from 0 to 100, and the y-axis shows the percent of subjects improved. Two lines depict the data: a solid line for Pregabalin and a dotted line for Placebo, with Pregabalin consistently showing higher improvement rates across the percent improvement range.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A text panel displaying a formula to calculate creatinine clearance (CLcr) based on age (years), weight (kg), and serum creatinine (mg/dL), with an adjustment factor of 0.85 for female patients. This formula is typically used for kidney function assessment.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin showing its molecular framework with carboxylic acid and amino functional groups attached to a branched carbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.